Sign In
Buy BBIO
$65.48
+1.60 (+2.50%)
At Close: Jun 03, 2026
3 Russell 2000 Stocks That Are About to Get Absolutely Crushed
05:34am, Monday, 18'th Dec 2023
For most of the year, the Russell 2000 has lagged far behind its peers, the S&P500 and the Nasdaq. However, the small-to-mid cap index appears to be closing the gap.
PALO ALTO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic dise
Why BridgeBio Pharma Was a Healthy Stock Today
07:57pm, Tuesday, 24'th Oct 2023
A well-respected financial services company initiated coverage on the biotech. It flagged it with its equivalent of a buy recommendation.
BridgeBio: Bets Acoramidis As The Pfizer Spoiler
11:05pm, Monday, 25'th Sep 2023
BridgeBio Pharma's Q2 2023 YoY revenue plummeted, but PIPE financing extends cash runway to 15 months, alleviating short-term liquidity concerns. Acoramidis poses a threat to Pfizer's tafamidis in ATT
BridgeBio's stock jumps 3.8% premarket after company announces $250 million PIPE financing led by Qatari sovereign fund
07:44am, Monday, 25'th Sep 2023
BridgeBio Pharma Inc.'s stock BBIO, +1.11% jumped 3.8% in premarket trade Monday, after the company announced a $250 million private investment in public equity, or PIPE, equity offering led by the Qa
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
08:08am, Wednesday, 13'th Sep 2023
The pharmaceutical industry is one of the most dynamic and innovative sectors in the world. It is constantly developing new drugs and treatments to address various health challenges and improve the qu
BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
07:30am, Thursday, 07'th Sep 2023
PALO ALTO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic dise
Andreas Halvorsen's Firm Ups Inhibrx Stake
04:26pm, Friday, 01'st Sep 2023
Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stake in Inhibrx Inc. ( INBX , Financial) by 7.71% fol
PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic dise
Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It?
10:07am, Wednesday, 09'th Aug 2023
This young biotech might soon commercialize a new medicine. Analysts see BridgeBio's shares headed upward.
Why Shares of BridgeBio Pharma Skyrocketed This Week
10:44am, Friday, 21'st Jul 2023
BridgeBio Pharma focuses on oncology and genetic diseases. The company said that acoramidis fared well in treating a heart muscle disease.
BridgeBio Pharma Surges on Positive Heart Drug News
10:25am, Tuesday, 18'th Jul 2023
BridgeBio Pharma ( BBIO , Financial) is a clinical-stage biopharmaceutical company that focuses on developing transformative medicines for patients with rare diseases. Its product pipeline categories
BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last?
06:04am, Tuesday, 18'th Jul 2023
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc
BridgeBio Pharma: Positive ATTR-CM Treatment Data Leads To Other 2023 Catalysts
06:42pm, Monday, 17'th Jul 2023
Primary endpoint met in BridgeBio Pharma, Inc.'s phase 3 ATTRibute-CM study, which used acoramidis for the treatment of patients with transthyretin amyloid cardiomyopathy; NDA filing expected before e
BridgeBio Pharma stock soars on heart disease drug study results
11:33am, Monday, 17'th Jul 2023
BridgeBio Pharma Inc shares surged 69% to $30.78 in late-morning trading on Monday after the commercial-stage biopharmaceutical company announced that Acoramidis, its drug development candidate for a
